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1 Introduction
Research into new markers for disease diagnosis, screening, and prognosis has ex-
ploded in recent years. In each of these settings, the primary question is of classi-
ﬁcation accuracy: How well does the marker distinguish between the two groups of
individuals, the “cases” and the “controls”?
The ROC curve plays a central role in evaluating classiﬁcation accuracy (Baker,
2003; Pepe et al., 2001). It displays the tradeoﬀ between false-positive and false
negative error rates associated with classiﬁcation rules based on the marker, Y . Let
D denote the binary group variable, “disease status”, and YD and YD¯ case and control
observations with survivor functions SD(y) = P [YD > y] and SD¯ = P [YD¯ > y]. The
ROC curve is a plot of the true-positive fraction (TPF) (sensitivity) versus the false-
positive fraction (FPF) (1 - speciﬁcity) for the rules which classify an individual
as “test-positive” if Y > c, where the threshold c varies over all possible values.
Equivalently, at a FPF = t, ROC(t) = P [YD > S
−1
D¯
(t)] = SD(S
−1
D¯
(t)) (Pepe, 2003).
There are commonly factors which aﬀect test accuracy. Understanding these ef-
fects helps to determine how the test should be used in practice. It may be that the
deﬁnition of testing positive on the basis of the marker should depend on covariates,
or it may be that the accuracy of the test is less than optimal in certain settings
(Pepe, 2003 [p. 48-49]). Patient characteristics, such as age, gender, or race, often
impact marker measurements. For example, younger women have more dense breasts,
which leads to more false positive errors when using a mammogram. Factors which
aﬀect the test itself, such as the expertise of the test operator, or variations in how
the test is performed, may also aﬀect test accuracy. The manner in which a biological
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specimen is collected, processed, or stored can greatly aﬀect the assay. Storage time
may be an important factor. Characteristics of disease also commonly aﬀect accu-
racy. More advanced disease is often easier to detect in cases, and controls may have
related conditions that increase the likelihood of false positive errors.
While the concept of covariate adjustment has been well studied in epidemiological
and clinical research, as well as in statistics more broadly, it has not been developed
in the classiﬁcation context. In this paper, we propose a covariate-adjusted summary
measure of classiﬁcation accuracy. We begin by motivating covariate adjustment in
the classiﬁcation setting. In Section 3, we deﬁne and give several interpretations
for the covariate-adjusted ROC curve. Section 4 proposes and provides distribution
theory for two novel estimators. Their small-sample performance is evaluated in
Section 5. In section 6, we illustrate these methods using data from the Physicians’
Health Study.
2 Background and Motivation
2.1 Covariate Eﬀects on Classiﬁcation Accuracy
There are two dimensions to the ROC curve, and hence two ways in which a covari-
ate can impact test accuracy (Pepe, 2003 [pp. 131 – 132]). Consider the traditional
“pooled” ROC curve, which ignores covariates by combining all case observations
together, regardless of covariate value, and all control observations together, regard-
less of covariate value. The pooled ROC describes the accuracy of rules that use a
common threshold to deﬁne test-positive. That is, the same threshold is used for all
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marker observations, regardless of their covariate values. If a covariate is associated
with marker observations among controls, then the use of a common threshold will
yield varying FPF’s across covariate groups. Hence, varying the covariate value has
the eﬀect of moving horizontally along the ROC curve. This is illustrated in Figure
1, adapted from Janes and Pepe (unpublished manuscript), which shows data for a
hypothetical marker, Y , and binary covariate, Z. The two points on the common
covariate-speciﬁc ROC curve are the operating characteristics of the positivity cri-
terion ‘Y > 2.5’ in the Z = 0 and Z = 1 populations. But the covariate may also
aﬀect the inherent discriminatory accuracy of the marker, i.e., the separation between
the YD and YD¯ distributions (the ROC curve) may vary with covariate value. This
is analogous to eﬀect modiﬁcation in the association setting. We initially focus on
covariates with only the ﬁrst type of covariate eﬀect. That is, we assume that the
separation between the YD and YD¯ distributions is the same in diﬀerent covariate
populations, as in Figure 1(a). For example, in a multi-center study, variations in
equipment or testing procedures may aﬀect marker levels equally in cases and con-
trols so that marker performance is similar across the study sites. More generally, any
covariate that causes a monotone transformation of Y that is independent of disease
status will not aﬀect ROC performance.
2.2 What is Covariate Adjustment for ROC Curves?
In therapeutic research, the covariate-adjusted treatment eﬀect is the eﬀect of treat-
ment within a population with ﬁxed covariate value. Similarly, in classic etiologic
epidemiology, the covariate-adjusted odds ratio is the odds associated with an expo-
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sure (or risk factor) among subjects with the same covariate values. In the absence of
eﬀect modiﬁcation by covariates, the covariate-adjusted eﬀect of treatment or expo-
sure is deﬁned to be the eﬀect that is common across covariate strata. Conceptually,
we stratify. In practice, covariate adjustment may be achieved by stratiﬁcation, when
covariates are discrete, or using regression methods.
We deﬁne covariate adjustment for ROC curves using an analogous approach.
The covariate-adjusted ROC curve for Y is the covariate-stratiﬁed ROC curve. In
other words, it is the ROC curve which characterizes the separation between YD and
YD¯ distributions in a population with ﬁxed covariate value. In Figure 1, this is the
common covariate-speciﬁc ROC curve (solid line).
We emphasize that covariate adjustment is diﬀerent from other roles for covariates
in marker evaluation, such as: 1) the performance of the covariate-adjusted risk score
for Y ; 2) the incremental value of Y over Z; 3) the performance of Y in a study where
controls are matched to cases with respect to Z; and 4) ROC regression which allows
the performance of Y to vary with Z.
Consider ﬁrst the covariate-adjusted risk score for Y , P [D = 1|Y, Z]. For example,
a logistic regression model for Y with adjustment for Z yields a linear predictor
β1Y + β2Z. The ROC curve for the linear predictor is not the ROC curve for Y
adjusted for Z, but rather it captures the ability of the combination of marker and
covariates to discriminate between cases and controls. Observe that this combination
may perform well even if Y is a poor classiﬁer if Z discriminates well. Figure 2
shows two examples where (Y, Z) is bivariate normal with mean (0, 0) and variance-
covariance matrix
⎛
⎜⎜⎝1 ρ
ρ 1
⎞
⎟⎟⎠ in controls, and mean (µY , µZ) and the same variance-
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covariance in cases. Under this model, the risk score, the optimal combination of Y
and Z for discrimination (McIntosh and Pepe, 2002), is (a monotone function of) a
linear combination of Y and Z. In Figure 2(a), Z is a good classiﬁer (µZ = 1.5) but
Y is not (µY = 0.5), and the two are relatively uncorrelated (ρ = 0.1). The linear
predictor performs well, but the covariate-adjusted ROC curve for Y , i.e. the ROC
curve for Y stratiﬁed by Z, is low because it relates to the discriminatory accuracy
of Y . In Figure 2(b), both Y and Z are good classiﬁers (µY = µZ = 1.5), but are
highly correlated (ρ = 0.9). The linear predictor performs well, as expected since it
should be at least as good as either marker on its own. However, after adjustment
for Z the ROC curve for Y is low because within a population where Z is ﬁxed, Y
is not a good discriminator. Most of its marginal discrimination is explained by Z,
with which it is highly correlated.
Consider the incremental value of the marker over the covariates. This is quantiﬁed
by comparing the ROC curve for the (Y, Z) combination to the ROC curve for Z alone.
This answers yet another question: How much does discriminatory accuracy improve
with the addition of Y to Z? It is easy to ﬁnd examples in which the incremental
value of Y is low, but the covariate-adjusted performance of Y is good, and where
the incremental value is large, but the covariate-adjusted performance of Y is poor
(Janes and Pepe, unpublished manuscript).
Matching of controls to cases is a design strategy commonly used to account for
covariate eﬀects on classiﬁcation accuracy. But the performance of Y in a study
matched on Z does not reﬂect its covariate-adjusted performance either. It is widely
appreciated in epidemiologic research that the analysis in a matched study must ad-
just for the matching covariates in order to appropriately estimate exposure or risk
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factor eﬀects. Analyses that do not adjust for matching covariates produce biased
estimates. A similar result was recently shown to hold for evaluation of classiﬁcation
accuracy from matched studies (Janes and Pepe, unpublished manuscript): the un-
adjusted ROC curve is biased downwards. Matching does not in and of itself adjust
for covariates. Rather, the analysis must also make these adjustments.
Finally, we note that ROC regression (Tosteson and Begg, 1988; Toledano and
Gatsonis, 1995; Pepe, 1998; Faraggi, 2003; Schisterman et al., 2004; Le, 1997; Pepe,
2000; Alonzo and Pepe, 2002; Cai and Pepe, 2002) is a methodology that investigates
if and how the discriminatory accuracy of the marker (the ROC curve) depends on co-
variates. This is analogous to eﬀect modiﬁcation in epidemiologic research and is not
the same as covariate adjustment. Figure 1 demonstrates that covariate adjustment
may be necessary even when the ROC curve does not vary with covariates.
2.3 Why Adjust for Covariates?
The pooled or unadjusted ROC curve has a number of drawbacks when there are
covariate eﬀects on test accuracy. Observe that the pooled ROC describes the per-
formance of the marker, including the portion of performance that is due to the
covariates. This is illustrated in Figure 1, scenario 1, wherein the pooled ROC lies
above the common covariate-speciﬁc ROC curve. For a real data example, consider
prostate-speciﬁc antigen (PSA), prostate cancer screening biomarker. The pooled
ROC curve for PSA is overly optimistic because it includes the portion of discrimi-
natory accuracy due to age: cases tend to be older than controls, and older subjects
tend to have higher PSA levels (Oesterling et al. 1993; Baillargeon et al., 2005). The
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performance of PSA conditional on age is of much more interest.
The use of a common threshold to deﬁne test-positive is another undesirable at-
tribute of the pooled ROC. For example, in the PSA setting, the use of a common
threshold will yield much higher FPF’s in older populations than in younger popula-
tions. This suggests that age-speciﬁc thresholds should be used to control the FPF
across age groups, as has been suggested in the literature (Oesterling et al. 1993).
In certain settings, failing to adjust for covariates will attenuate the ROC curve.
In particular, if the covariate aﬀects the marker in the same way in cases and controls
and is independent of disease status, the pooled ROC curve will lie below the common,
covariate-speciﬁc ROC curve (Pepe, 2003 [p. 133–134]). This is illustrated in Figure
1, scenario 2. In the radiology literature, attenuation of the ROC curve associated
with pooling data from multiple readers who use the rating scales diﬀerently is well
known (Swets and Pickett, 1982 [p. 65]; Hanley, 1989; Rutter and Gatsonis, 2001).
Recently this phenomenon has been highlighted as a general issue in matched case-
control studies (Janes and Pepe, unpublished manuscript).
3 The AROC
Consider a continuous marker, Y , and continuous covariate, Z. Let ZD and ZD¯
denote case and control covariate observations with cumulative distribution functions
(CDF) PZD and PZD¯ . Denote by SDZ(y) = P [YD > y|Z] and SD¯Z = P [YD¯ > y|Z] the
continuous survivor functions for Y conditional on Z, fDZ and fD¯Z the corresponding
densities, and ROC(t) = SDZ(S
−1
D¯Z
(t)) the common covariate-speciﬁc ROC curve. Our
methods generalize naturally to a discrete covariate or multiple covariates.
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3.1 Deﬁnition and Interpretations
The covariate-adjusted ROC curve is deﬁned as the common covariate-speciﬁc ROC
curve for Y , and denoted by AROC = SDZ(S−1D¯Z(t)) to emphasize its adjusted or
stratiﬁed nature. Mathematically,
AROC(t) = P [YD > S−1D¯ZD(t)], (1)
where the covariate-speciﬁc thresholds, S−1
D¯Z
(t), yield FPF = t among controls with
covariate value Z. In other words, the AROC is a plot of the TPF versus the FPF
for the set of rules that classify a subject with covariate value Z as positive if Y > cZ ,
where cZ = S
−1
D¯Z
(t) is the Z-speciﬁc threshold associated with a FPF of t. Using these
rules, the marginal FPF is also equal to t.
Several other interpretations can be provided for the covariate-adjusted ROC
curve. We write the AROC as
AROC(t) = P [SD¯ZD(YD) ≤ t]. (2)
This reveals that the AROC is the CDF of SD¯ZD(YD), the placement of a case
observation relative to a reference distribution of controls with the same covari-
ate value as the case. Contrast this with the unadjusted or pooled ROC curve,
ROC(t) = P [SD¯(YD) ≤ t], which is the CDF of a case observation standardized
relative to the general control distribution (Pepe and Cai, 2002).
Another interpretation for the AROC follows from marker standardization. Let
Y ∗ = 1−SD¯Z(Y ) be the percentile for Y in the control population with the appropriate
covariate value. Such standardization is used, for example, to standardize children’s
weights relative to height and gender (Hammill et al., 1977). The AROC is simply
the pooled ROC curve for Y ∗ (this follows because 1− SD¯ZD¯(YD¯) ∼ Uniform[0, 1]).
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The AROC has some attractive mathematical properties. It is invariant with
respect to monotone increasing transformations of Y and/or Z. It is also unaﬀected
by control covariate-dependent sampling (e.g., matching). This follows because such
a design samples controls randomly conditional on Z, and cases are a simple random
sample from the case population.
Exploring the ordering of the pooled and adjusted ROC curves is useful for iden-
tifying scenarios in which failing to adjust for covariates leads to bias, and for de-
termining the direction and magnitude of the bias. The mathematical relationship
between the two ROC curves is complex. In one trivial case, they are the same: if
the distribution of YD¯ is independent of Z, the Z-speciﬁc thresholds associated with
a ﬁxed FPF do not vary. If, on the other hand, Z is independent of D and does
not aﬀect the discriminatory capacity of Y , the pooled ROC curve will lie below the
AROC (Pepe, 2003 [p. 135]). More generally, the ordering of the two ROC curves
depends on the distributions of Y and Z and the associations between them and of
each with disease status. In a classical distributional case (the binormal model), the
ordering is somewhat intuitive (Janes and Pepe, 2006). The pooled ROC will lie
above the AROC if the association between Z and D is stronger than the association
between Y and D, since it includes the portion of discriminatory accuracy due to
Z. However, the AROC rule will yield gains in accuracy if the association between
Y and D is stronger than the association between Z and D, and if in addition the
correlation between YD¯ and ZD¯ is large. Larger correlation between YD and ZD will
further improve the AROC relative to the pooled ROC.
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3.2 When Covariates Aﬀect Discrimination
When Z aﬀects discrimination, covariate-speciﬁc ROC curves, ROCZ(t) = SDZ(S
−1
D¯Z
(t)),
are of interest. A wide variety of methods for estimating covariate-speciﬁc ROC curves
have been proposed (see, e.g., Tosteson and Begg, 1988; Toledano and Gatsonis, 1995;
Pepe, 1998; Faraggi, 2003; Schisterman et al., 2004; Le, 1997; Pepe, 2000; Alonzo and
Pepe, 2002; Cai and Pepe, 2002). These methods allow for covariate eﬀects on both
the FPF’s (or thresholds) and on the ROC curve itself.
Interestingly, the AROC is a simple summary of covariate-speciﬁc ROC curves:
AROC(t) =
∫
P [YD > S
−1
D¯ZD
(t) | ZD = Z] dPZD(Z)
=
∫
ROCZ(t) dPZD(Z). (3)
Equivalently, AROC(t) = EZD [ROCZD(t)]. The AROC reports a weighted average
of covariate-speciﬁc TPF’s, holding the covariate-speciﬁc FPF’s constant. This is a
useful summary of covariate-adjusted accuracy, particularly for small studies where
covariate-speciﬁc ROC curves cannot be estimated with precision. It also provides a
single summary of covariate-adjusted accuracy with which to compare markers.
4 Estimation of the AROC
4.1 Estimators
We propose two estimators for AROC(t) = P [YD > S−1D¯ZD(t)] using nD and nD¯ case
and control observations, where nDZ and nD¯Z are the numbers of each with covariate
value Z. In both instances, we estimate the outside probability empirically. The re-
maining task is estimation of the control quantiles, S−1
D¯Z
(t). With the non-parametric
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estimator, valid for a discrete covariate (Z = 1, . . . , K), we use empirical quantiles
in each stratum. With the semi-parametric estimator, the quantiles are estimated
based on a model for the distribution of YD¯ as a function of ZD¯. Here we lay out the
general framework for the AROC estimator, of which the non-parametric estimator
is a special case.
Suppose we assume the quantile model, YD¯ = f(ZD¯, ; θ), where  is random
error and θ are parameters. With the semi-parametric AROC estimator, this model
may be parametric, such as a normal linear model, or semi-parametric (see, e.g.,
Heagerty and Pepe, 1999). The model induces a form for the control quantiles. Let
qZ(t; θ) = S
−1
D¯Z
(t; θ) be the function which extracts the 1− t quantile from the set of
control quantiles with covariate value Z, where qZ(t; θˆ) = S
−1
D¯Z
(t; θˆ) is the estimated
quantile. We write
̂AROCθˆ(t) =
1
nD
nD∑
i=1
I
[
YDi > qZDi (t; θˆ)
]
.
With the non-parametric estimator, θ =
(
S−1
D¯Z=1
(t), . . . , S−1
D¯Z=K
(t)
)T
are the quantiles
themselves, SˆD¯Z(y) = n
−1
D¯Z
∑nD¯Z
i=1 I
[
YD¯Zi > y
]
, and qZ(t; θˆ) = Sˆ
−1
D¯Z
(t) =
inf
s∈[0,1]
{
SˆD¯Z(s) ≥ t
}
. This estimator depends only on the ranks of the data, and thus
is invariant with respect to monotone transformations.
4.2 Asymptotic Distribution Theory
We assume the following conditions in establishing asymptotic distribution theory.
Recall that the distribution of YD is not a function of θ.
C(1) Random sampling conditional on D, nD + nD¯ →∞, and nDnD¯ → λ ∈ (0, 1).
C(2)
√
nD¯ (θˆ − θ) d−→ N(θ,Σθ) as nD¯ →∞.
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C(3) AROCθ(t) is diﬀerentiable, and hence continuous, in θ.
C(4) lim
nD¯→∞
P [AROCθˆ(t) /∈{0, 1}] = 1, where AROCθˆ(t) = P [YD > qZD(t; θˆ) | θˆ] is
the AROC based on estimated quantiles.
C(5) t /∈ {0, 1}.
We note in relation to C(1) that covariate-dependent sampling can also be accom-
modated (see Section 4.4). A wide variety of quantile models satisfy C(2), including
parametric (Cole, 1990; Cole and Green, 1992; Pepe, 2003 [p. 140]), semi-parametric
(Heagerty and Pepe 1999; Zheng 2002), empirical (proven in appendix A.2), and
any θˆ based on unbiased estimating equations satisfying standard regularity condi-
tions. C(3) is also valid for a diversity of quantile and ROC models, such as the
location-scale quantile model (Heagerty and Pepe, 1999) with bounded ∂
∂t
ROCZ(t)
and E(ZD) < ∞ (Janes and Pepe, 2006). C(4) is violated if the support of the
case distribution is entirely above or below the estimated quantile of interest. This
will not occur as long as the support of the YD distribution includes the support of
the YD¯ distribution, or if the support of the YD distribution is unbounded (e.g.,the
normal distribution). We also require that t /∈ {0, 1}, but by deﬁnition AROC(0) = 0
and AROC(1) = 1. Finally, imposing continuity of SDZ(y) and SD¯Z(y) implies that
ROCZ(t) = SDZ(S
−1
D¯Z
(t)) and AROC(t) = EZD [ROCZD(t)] are continuous in t.
Theorem 1 Under C(1)-C(5),
√
nD (̂AROCθˆ(t)−AROCθ(t))
d−→ N(0, V (t)) as
nD, nD¯ →∞, where
V (t) = AROCθ(t) (1−AROCθ(t)) + λ · ∂
∂θ
AROCθ(t) Σθ ∂
∂θ
AROCθ(t)T (4)
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(proven in appendix A.1).
The form of V (t) is quite intuitive. The second component comes from estimat-
ing the Z-speciﬁc quantiles, while the ﬁrst is a binomial variance associated with
estimating the TPF, given the quantiles.
For the non-parametric AROC estimator, C(2) and C(3) are satisﬁed when
C(6) fD¯Z(y) is continuous and positive in a neighborhood of S
−1
D¯Z
(t) ∀Z,
and V (t) reduces to
V (t) = AROCθ(t) (1−AROCθ(t)) + λ ·
K∑
Z=1
p2ZD(Z)
pZD¯(Z)
· fDZ(S
−1
D¯Z
(t))2
fD¯Z(S
−1
D¯Z
(t))2
· t(1− t), (5)
where pZD(Z) and pZD¯(Z) are the probability mass functions for ZD and ZD¯ (proven
in appendix A.2).
4.3 Consistent Variance Estimation
We propose two variance estimators. The ﬁrst can be used to estimate the vari-
ance of the semi-parametric AROC estimator, (4). The semi-parametric estimator
is consistent by Theorem 1. We assume that a consistent estimator of Σθ exists
(e.g., if θˆ is based on a set of unbiased estimating equations, a sandwich-type vari-
ance estimator can be used). The jth component of ∂
∂θ
AROCθ(t) is estimated by
̂AROCθˆ+hj(n)(t)−̂AROCθˆ−hj(n)(t)
2h(n)
, where h(n) is o(n
−1/3
D ), and θˆ+h
j(n) (θˆ−hj(n))
denotes the vector θˆ with h(n) added to (subtracted from) the jth component only.
The composite variance estimator is shown to be consistent in appendix A.3, under
C(1)-C(5), and
C(7) lim
nD¯→∞
P [̂AROCθˆ+hj(n)(t) /∈{0, 1}] = limnD¯→∞P [̂AROCθˆ−hj(n)(t) /∈{0, 1}] = 1, ∀j.
14
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With small sample sizes, the ∂
∂θj
AROCθ(t) estimate may be sensitive to the choice
of bandwidth, h(n). We have used h(n) = 0.04 in applications and simulations; in
one example this ensured
AROCθ+hj(n)(t)−AROCθ−hj(n)(t)
2h(n)
≈ ∂
∂θj
AROCθ(t). This
value has worked well. We leave exploration of the optimal choice of h(n) for future
research.
Our second variance estimator can be used to estimate the variance of the non-
parametric AROC estimator, (5). Here, AROCθ(t) is estimated using the non-
parametric estimator, pZD(Z) and pZD¯(Z) using binomial proportions, S
−1
D¯Z
(t) em-
pirically, and fDZ(y) and fD¯Z(y) with uniformly consistent kernel density estimates
(Silverman 1986 [Section 3.7]). In appendix A.4, we prove that the composite function
is consistent under C(1)-C(6), and
C(8) fDZ(y) and fD¯Z(y) are continuous density functions ∀Z.
Bootstrap variance estimation is a simple alternative which accommodates clus-
tered sampling and performs well in practice and in small sample simulations (see
Section 5).
4.4 Sampling Based on Covariates
In many situations, sampling may depend on both D and Z. Two simple examples
are matching, in which controls are sampled to have the same Z distribution as the
cases, and sampling subjects in a speciﬁed Z range, say conditional on Z > z0. With
such designs, our results continue to hold, but all population distributions should be
replaced with sampling distributions in the asymptotic distributions of the estimators.
For example, if sampling is conditional on D and Z > z0, SD(y) and SD¯(y) should be
15
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replaced with P [YD > y | Z > z0] and P [YD¯ > y | Z > z0], respectively.
4.5 Estimation of the AROC using ROC-GLM
The AROC can also be estimated using ROC-GLM, a method originally proposed
for estimating covariate-speciﬁc ROC curves (Pepe, 2000; Alonzo and Pepe, 2002).
ROC-GLM requires estimating the covariate-speciﬁc control quantiles using any of the
existing approaches, and specifying and ﬁtting a model for the ROC curve, typically
as a function of covariates:
g(ROCZ(t)) = g
(
P [SD¯ZD(YD) ≤ t | ZD = Z]
)
= h0(t) + βZ,
where g and h0 are monotone functions on (0,1). A model for the AROC is obtained
by including Z in the quantile calculations, while omitting Z from the ROC model,
g(AROC(t)) =h0(t). An example is the binormal model, AROC(t) = Φ(α+βΦ−1(t)),
where Φ is the standard normal CDF. This approach assumes a parametric form for
the AROC, but the marker distributions remain unspeciﬁed. A smooth estimate of
the AROC results. The version of ROC-GLM in which h0(t) is estimated empirically
(Cai and Pepe, 2002) reduces to our semi-parametric estimator of the AROC.
5 Small Sample Performance of Proposed Estima-
tors
In this section, we evaluate the ﬁnite sample properties of the AROC estimators using
simulations. We ﬁrst evaluate the non-parametric estimator and its variance, which
can be used for discrete Z. We assume Y is normally distributed conditional on a
16
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binary covariate, Z = 0, 1, where YD¯ | Z = 0 ∼ N(0, 1), YD¯ | Z = 1 ∼ N(µD¯1 , 1),
YD | Z = 0 ∼ N(µD0 , 1), and YD | Z = 1 ∼ N(µD1 , 1). The induced AROC is
AROCθ(t) = P [ZD = 0] Φ(µD0 + Φ−1(t)) + P [ZD = 1] Φ(µD1 − µD¯1 + Φ−1(t)), (6)
and the asymptotic variance of the non-parametric estimator is
V (t)
nD
=
AROCθ(t) (1−AROCθ(t))
nD
+
P [ZD = 0]
2
P [ZD¯ = 0]
(
φ(µD0 + Φ
−1(t))
φ(Φ−1(t))
)2
· t(1− t)
nD¯
+
P [ZD = 1]
2
P [ZD¯ = 1]
(
φ(µD1 − µD¯1 + Φ−1(t))
φ(Φ−1(t))
)2
· t(1− t)
nD¯
, (7)
where φ is the standard normal density function. Due to the invariance of the AROC
with respect to monotone transformations, this model simply assumes that there
exists a monotone increasing transformation which makes Y normal in cases and
controls, conditional on Z. All of the assumptions laid out in Section 4 are satisﬁed
under this model. We set µD¯1 = 0.2, µD0 = 0.9, µD1 = 0.9, P [ZD¯ = 1] = 0.7, and
P [ZD = 1] = 0.3 and consider estimation at t = 0.05, 0.10, 0.20, 0.50. The AROC
values are 0.21, 0.33, 0.50, 0.80 and the two components of asymptotic variance are
n−1D (0.33, 0.44, 0.50, 0.32) and n
−1
D¯
(1.41, 1.40, 1.14, 0.40).
We simulated 5,000 datasets, where nD = nD¯ varies between 100 and 1,000 (see Ta-
ble 1). Note that, with nD = nD¯ = 100 and P [ZD = 1] = 0.3, there are approximately
30 cases with Z = 1. In terms of percent bias, deﬁned as
avg(̂AROCθˆ(t))−AROCθ(t)
AROCθ(t) ,
where avg(̂AROCθˆ(t)) is the average AROC estimate, the AROC estimator performs
very well, except for some modest bias when both t and nD = nD¯ are small. The
percent bias in the non-parametric variance estimate (using rectangular kernel den-
sity estimates) is deﬁned as
median ( ˆV (t))− V̂ ar(̂AROCθˆ(t))
V̂ ar(̂AROCθˆ(t))
, where the median
variance estimate is calculated because of the skewed distribution of the variance es-
timates, and V̂ ar(̂AROCθˆ(t)) is the sample variance in the AROC estimates. The
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variance estimator tends to underestimate the true variance, and most of this bias
comes from estimating the second component of variance. There is substantial bias
when t is small, but this disappears for larger t. The percent diﬀerence between the
asymptotic and sample variances of the AROC estimates, V (t)− V̂ ar(
̂AROCθˆ(t))
V̂ ar(̂AROCθˆ(t))
,
shows that they tend to be close, with diﬀerences only when both t and nD = nD¯ are
small. Coverage probabilities based on non-parametric variance estimates are pro-
vided. Coverage based on logit transformations, which have been shown to improve
coverage for the pooled ROC when t is close to 0 or 1 (Pepe, 2003 [p. 102]), are also
shown. Only logit-based coverage is shown when both t and nD = nD¯ are small, since
AROC estimates are frequently close to zero. We ﬁnd that coverage can be low with
small t, but is very good for moderate t.
We also evaluate the performance of bootstrap variance estimates. Data is resam-
pled 100 times conditional on D, and the sample variance of the AROC estimates is
calculated. The percent bias in the bootstrap variance estimate, deﬁned as with the
non-parametric variance estimates, shows substantially less bias. Bootstrap coverage
also tends to be better; coverage is good except when both t and nD = nD¯ are small.
We compare non-parametric AROC estimates with semi-parametric estimates,
based on a normal linear quantile model. Table 2 displays the percent diﬀerence
in the estimates, deﬁned as avg
(
̂AROCθˆ;semi(t)−̂AROCθˆ(t)
)
/AROCθ(t), where
̂AROCθˆ(t) is the non-parametric estimate,̂AROCθˆ;semi(t) is the semi-parametric es-
timate, and the average is taken over 5,000 simulations. The estimates agree quite
well. The estimated relative eﬃciency of the two estimators,
V̂ ar(̂AROCθˆ;semi(t))
V̂ ar(̂AROCθˆ(t))
,
where the variance is estimated over the 5,000 simulations, is also shown. The semi-
parametric estimator yields substantial gains in eﬃciency, with larger gains for smaller
18
Hosted by The Berkeley Electronic Press
t and larger nD = nD¯.
We explore the performance of the semi-parametric AROC estimator and its vari-
ance under the double binormal model (Lin and Jeon, 2003),⎛
⎜⎜⎝YD¯
ZD¯
⎞
⎟⎟⎠ ∼ BV N
⎛
⎜⎜⎝
⎛
⎜⎜⎝µYD¯
µZD¯
⎞
⎟⎟⎠ ,
⎛
⎜⎜⎝ σ
2
YD¯
σYD¯σZD¯ρD¯
σYD¯σZD¯ρD¯ σ
2
ZD¯
⎞
⎟⎟⎠
⎞
⎟⎟⎠
⎛
⎜⎜⎝YD
ZD
⎞
⎟⎟⎠ ∼ BV N
⎛
⎜⎜⎝
⎛
⎜⎜⎝µYD
µZD
⎞
⎟⎟⎠ ,
⎛
⎜⎜⎝ σ
2
YD
σYDσZDρD
σYDσZDρD σ
2
ZD
⎞
⎟⎟⎠
⎞
⎟⎟⎠ . (8)
This is an extension of the classic binormal model for the pooled ROC curve (Swets,
1986; Hanley, 1988, 1996). The induced AROC is a binormal ROC curve with in-
tercept and slope parameters
µYD−µYD¯
s·σZD
− ρD¯σYD¯ (µZD−µZD¯ )
s·σZ
D¯
σZD
and
σY
D¯
σZD
√
1−ρ2
D¯
s
, where
s =
√
σ2
YD
σ2
ZD
(1− ρ2D) +
(
ρD¯
σY
D¯
σZ
D¯
− ρD σYDσZD
)2
(Janes and Pepe, 2006). Again, this model
is more general than it ﬁrst appears; it stipulates that there exists a monotone, in-
creasing function which transforms (Y, Z) to bivariate normality in cases and controls
(Janes and Pepe, 2006). All of the assumptions laid out in Section 4 are satisﬁed
under this model. We apply the semi-parametric AROC estimator using a normal
linear quantile model; this is the true model for YD¯ given ZD¯. We set µYD¯ = µZD¯ = 0,
σYD¯ = σYD = 1, σZD¯ = σZD = 1.5, ρD = 0.6, ρD¯ = 0.2, µYD = 0.7, and µZD = 0.5. The
AROC values at t = 0.05, 0.10, 0.20, 0.50 are 0.16, 0.25, 0.39, 0.67. The two compo-
nents of asymptotic variance are n−1D (0.24, 0.37, 0.49, 0.36) and n
−1
D¯
(0.35, 0.53, 0.56, 0.23).
We simulated 5,000 datasets, where nD = nD¯ varies between 100 and 1,000. The
AROC estimator performs very well, except for some modest small sample bias for
very small nD = nD¯ and t (see Table 3). The semi-parametric variance estimator
exhibits moderate small sample bias for the smallest sample sizes; the variance is
consistently overestimated. This is primarily due to bias in the second component of
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variance, which involves ∂
∂θ
AROCθ(t). Yet, coverage is reasonable. The asymptotic
and sample variances agree quite well, except for some minor diﬀerences with the
smallest sample sizes. Bootstrap variance estimates are good alternatives: they tend
to exibit less bias, and have excellent coverage.
In summary, using quite general simulation models, we have found that theAROC
estimators perform reasonably well in small samples. Varying parameter choices have
produced similar or improved performance.
6 Illustration
We illustrate our methods using data from the Physicians’ Health Study (PHS) (Gann
et al., 2002). The PHS was a randomized, placebo-controlled study of aspirin and
β-carotene among 22,071 US male physicians ages 40 to 84 years in 1982. A blood
sample taken at enrollment was stored. For 429 men diagnosed with prostate cancer
up to 12 years after enrollment (most before PSA was widely used for screening), and
for 1,287 controls not diagnosed with prostate cancer during 12 years of follow-up,
the serum was assayed for PSA. Controls were matched to cases with respect to age;
for each case, three controls were selected who were within one year of age (Gann et
al., 2002; Etzioni et al., 2004).
The goal of this sub-study is to determine how well PSA discriminates between
men who did and did not go on to develop prostate cancer. The pooled ROC
curve in the matched data is not of practical interest (Janes and Pepe, unpublished
manuscript). It describes the ability of PSA to distinguish between cases and age-
matched controls, an artiﬁcially constructed control group. More importantly, this
20
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ROC curve is attenuated by matching on age in the design. We use the AROC to
summarize the age-adjusted discriminatory accuracy of PSA.
Age-speciﬁc ROC curves for PSA, estimated using a binormal ROC-GLM model
(Alonzo and Pepe, 2002), with quantiles based on a linear location-scale model (Hea-
gerty and Pepe, 1999), are shown in Figure 3(a). Observe that there is very little
variation in discrimination due to age. Hence, the AROC represents the common,
age-speciﬁc ROC curve for PSA, and is a good summary of PSA performance.
The AROC for PSA is shown in Figure 3(b), estimated both using the semi-
parametric estimator and using a binormal ROC-GLM model, where the control
quantiles are estimated using a linear location-scale model (Heagerty and Pepe, 1999)
for both methods. Bootstrapping is used for inference, and logit-based conﬁdence
intervals are overlaid at t = 0.025 and t = 0.05. The AROC describes the ability of
PSA to discriminate between cases and controls of the same age. Using ROC-GLM,
we estimate that 18% of cases can be detected (95% CI: 14% to 23%) when the age-
speciﬁc FPF is held at 0.025, and 27% cases can be detected (95% CI: 23% to 32%)
when the common FPF is increased to 0.05.
7 Discussion
We have proposed the AROC as a measure of covariate-adjusted discriminatory accu-
racy. This is the common covariate-speciﬁc ROC curve when the covariate does not
aﬀect discrimination, and a weighted average of covariate-speciﬁc ROC curves when
the covariate does aﬀect discrimination. Asymptotic distribution theory was devel-
oped for our non-parametric and semi-parametric AROC estimators, which perform
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reasonably well in small samples. The consistent variance estimators also have good
small sample performance, but bootstrap variance estimation is easier to implement
and provides improved coverage. We have used the asymptotic variance expressions
to investigate eﬃcient study design (Janes and Pepe, unpublished manuscript). An
intriguing result is that matching of controls to cases is optimal when covariates aﬀect
the marker but not discrimination. The optimal case-control ratio also follows from
the variance expressions.
Covariate adjustment is important for covariates which aﬀect marker observations
but not discrimination. Their eﬀects must be adjusted for to avoid bias in ROC
estimation. However, covariates which are markers in their own right might be better
combined with the marker in the risk score in order to examine the value of the
combination or the incremental value of the marker over the covariates. Covariates
which aﬀect discrimination should be used to estimate covariate-speciﬁc ROC curves.
The AROC can be used in such situations to summarize the covariate-speciﬁc ROC
curves. This may be particularly useful for comparing the performance of markers.
Methods to compare covariate-adjusted ROC curves are under development.
The AROC is a simple vertical average of covariate-speciﬁc ROC curves. This is
just one of many possible ways of summarizing covariate-speciﬁc ROC curves. Our
approach is appealing because it results in a true ROC curve, i.e., a plot of the TPF
versus FPF for a set of classiﬁcation rules. Many potential summary measures are
not true ROC curves. The AROC also makes sense in applications where controlling
the FPF across covariate groups is desirable (e.g., cancer screening). There are ap-
plications, however, where controlling the covariate-speciﬁc false negative fractions is
more appropriate; this suggests averaging horizontally. The vertical and horizontal
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ROC averages are exactly the same when the covariates do not aﬀect discrimination,
but diﬀer more generally. The horizontal version, a simple extension of our methods,
describes the accuracy of rules which classify using covariate-speciﬁc thresholds that
control the covariate-speciﬁc false negative fractions.
The area under the AROC, the A-AUC, can be interpreted as the probability
of correctly ordering a randomly chosen case and control observation with the same
covariate value, A-AUC = P [YD > YD¯ZD ]. This statistical summary deserves further
development and might serve as the basis of tests to compare covariate-adjusted ROC
curves for diﬀerent markers.
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Appendix
A.1 Proof of Theorem 1 We write
√
nD (̂AROCθˆ(t)−AROCθ(t)) =
√
nD
(
̂AROCθˆ(t)−AROCθˆ(t)
)
+
√
nD (AROCθˆ(t)−AROCθ(t))
=
1√
nD
nD∑
i=1
I
[
YDi > qZDi (t; θˆ)
]
− P [YD > qZD(t; θˆ) | θˆ]
+
√
nD
(
P [YD > qZD(t; θˆ) | θˆ]− P [YD > qZD(t; θ)]
)
≡ An + Bn.
Note that Bn =
√
nD (g(θˆ)− g(θ)), and by C(1)-C(3), the delta method (Ferguson
1996 [p. 45]) and Slutsky’s Theorem, Bn
d−→ N(0, σ2b ) as nD, nD¯ →∞, where
σ2b = λ
∂
∂θ
AROCθ(t) Σθ ∂∂θAROCθ(t)T . Now, we write An = 1√nD
∑nD
i=1 Ani and ﬁnd
its asymptotic distribution conditional on θˆ, using the Lindeberg-Feller Central Limit
Theorem (LFCLT). First, note that E[Ani | θˆ ] = 0 and V ar[Ani| θˆ ] = AROCθˆ(t) (1−
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AROCθˆ(t)). Convergence under the LFCLT requires that
1
nD AROCθˆ(t) (1−AROCθˆ(t))
nD∑
i=1
E[A2niI [|Ani| ≥  nDAROCθˆ(t) (1−AROCθˆ(t))]]
(1 a)
converges to zero as nD →∞ for all  > 0. But A2niI[| Ani | ≥  · nD AROCθˆ(t)
(1−AROCθˆ(t))] takes the value (1−AROCθˆ(t))2 · I
[
1
AROCθˆ(t)
≥ nD
]
with prob-
ability AROCθˆ(t), and AROCθˆ(t)2 · I
[
1
1−AROCθˆ(t)
≥ nD
]
, with probability 1
−AROCθˆ(t). Hence,(1a) becomes (1−AROCθˆ(t)) · I
[
1
AROCθˆ(t)
≥ nD
]
+AROCθˆ(t)·
I
[
1
1−AROCθˆ(t)
≥ nD
]
. C(4) and C(5) ensure that this converges to zero. Thus,
conditional on θˆ,
An√AROCθˆ(t) (1−AROCθˆ(t))
d−→ N(0, 1) as nD → ∞. Finally,
the asymptotic distribution of
An√AROCθˆ(t) (1−AROCθˆ(t)) conditional on θˆ is the
same as that of
An√AROCθˆ(t) (1−AROCθˆ(t)) conditional on Bn, since it is func-
tionally independent of θˆ and Bn =
√
nD (g(θˆ) − g(θ)). By C(2) and C(3),
AROCθˆ(t) (1−AROCθˆ(t))
P−→ AROCθ(t) (1−AROCθ(t)) as nD¯ → ∞. By Slut-
sky’s Theorem,
⎛
⎜⎜⎜⎝
An√
AROCθ(t) (1−AROCθ(t))
Bn
⎞
⎟⎟⎟⎠ d−→ BV N
⎛
⎜⎜⎝
⎛
⎜⎜⎝0
0
⎞
⎟⎟⎠ ,
⎛
⎜⎜⎝1 0
0 σ2b
⎞
⎟⎟⎠
⎞
⎟⎟⎠ as
nD, nD¯ →∞. The continuous mapping theorem then yields the desired result.
A.2 Non-Parametric Estimation of the AROC We prove that C(2) and C(3)
are satisﬁed with empirical quantile estimates. Under C(6), by standard empirical
process theory,(Ferguson 1996 [p. 91]), for a ﬁxed stratum Z and conditional on nD¯Z ,
√
nD¯Z
(
Sˆ−1
D¯Z
(t)− S−1
D¯Z
(t)
)
d−→ N(0, σ2Z) as nD¯Z → ∞, where σ2Z = t(1−t)f2
D¯Z
(S−1
D¯Z
(t))
. By
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C(1), nD¯Z
nD¯
P−→ pZD¯(Z) as nD¯ →∞. Hence, for all , there exists N such that
P [
√
nD¯Z
(
Sˆ−1
D¯Z
(t)− S−1
D¯Z
(t)
)
≤ y] = E[P [√nD¯Z
(
Sˆ−1
D¯Z
(t)− S−1
D¯Z
(t)
)
≤ y | nD¯Z ]]
= E[P [
√
nD¯Z
(
Sˆ−1
D¯Z
(t)− S−1
D¯Z
(t)
)
≤ y | nD¯Z ] I [nD¯Z > N ]]
+ E[P [
√
nD¯Z
(
Sˆ−1
D¯Z
(t)− S−1
D¯Z
(t)
)
≤ y | nD¯Z ] I [nD¯Z ≤ N ]]
< (Φ(y/σZ) + ) · P [nD¯Z > N ]
+ E[P [
√
nD¯Z
(
Sˆ−1
D¯Z
(t)− S−1
D¯Z
(t)
)
≤ y | nD¯Z ] I [nD¯Z ≤ N ]].
Since nD¯Z →∞, the second term can be made arbitrarily small, and P [nD¯Z > N ] ar-
bitrarily close to 1, by choosing N large enough. Thus,
√
nD¯Z(Sˆ
−1
D¯Z
(t)−S−1
D¯Z
(t))
d−→
N(0, σ2Z), and by Slutsky’s Theorem,
√
nD¯(Sˆ
−1
D¯Z
(t) − S−1
D¯Z
(t))
d−→ N(0, σ2Z
pZ
D¯
(Z)
) as
nD¯ → ∞. Because observations in diﬀerent strata are independent, marginal con-
vergence implies joint asymptotic normality, with variance-covariance matrix Σθ =
diag
(
σ2
Z
pZ
D¯
(Z)
)
. We also calculate the form of ∂
∂θ
AROCθ(t). We have
∂
∂θZ
AROCθ(t) = ∂
∂S−1
D¯Z
(t)
EZD [P [YD > S
−1
D¯ZD
(t) | ZD]]
= −EZD [fDZD(S−1D¯ZD(t)) ·
∂
∂S−1
D¯Z
(t)
S−1
D¯ZD
(t)]
= −fDZ
(
S−1
D¯Z
(t)
) · pZD(Z),
and V (t) reduces to (5).
A.3 We prove consistency of the estimated asymptotic variance of the semi-parametric
AROC estimator. We write the estimate of ∂
∂θj
AROCθ(t) as
̂AROCθˆ+hj(n)(t)−AROCθ+hj(n)(t)
2h(n)
+
AROCθ+hj(n)(t)−AROCθ−hj(n)(t)
2h(n)
−
̂AROCθˆ−hj(n)(t)−AROCθ−hj(n)(t)
2h(n)
. (2 a)
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Consider the ﬁrst component. We claim that
√
nD(̂AROCθˆ+hj(n)(t)−AROCθ+hj(n)(t))
d−→ N(0, V (t)). The proof of this fact is very similar to the proof that√nD(̂AROCθˆ(t)−
AROCθ(t)) is asymptotically normal, and hence Op(1), proven in appendix A.1.
Hence,
√
nD(̂AROCθˆ+hj(n)(t)−AROCθ+hj(n)(t))
2
√
nDh(n)
P−→ 0, since the denominator con-
verges to ∞. A similar argument can be used to prove that the third term in (2a)
converges to 0. Finally,
AROCθ+hj(n)(t)−AROCθ−hj(n)(t)
2h(n)
P−→ ∂
∂θ
AROCθ(t), by
continuity ofAROCθ(t) in θ (assumption C(3)). Hence, our estimate of ∂∂θjAROCθ(t)
is consistent. Now, with Σˆθ
P−→ Σθ, ̂AROCθˆ(t)
P−→ AROCθ(t), and consistency of
the derivative estimator, we have consistency of the composite variance estimator.
A.4 We prove consistency of the estimated asymptotic variance of the non-parametric
AROC estimator. We have pˆZD(Z) P−→ pZD(Z) and pˆZD¯(Z)
P−→ pZD¯(Z) for all
Z = 1, . . . , K, and by standard empirical process theory, (Ferguson 1996 [p. 91])
under C(6), Sˆ−1
D¯Z
(t)
P−→ S−1
D¯Z
(t) as nD¯ →∞. We write
| fˆDZ(Sˆ−1D¯Z(t))− fDZ(S−1D¯Z(t)) | =
| fˆDZ(Sˆ−1D¯Z(t))− fDZ(Sˆ−1D¯Z(t)) + fDZ(Sˆ−1D¯Z(t))− fDZ(S−1D¯Z(t)) |
≤ | fˆDZ(Sˆ−1D¯Z(t))− fDZ(Sˆ−1D¯Z(t)) | + | fDZ(Sˆ−1D¯Z(t))− fDZ(S−1D¯Z(t)) | .
The ﬁrst term converges in probability to zero by the uniform consistency of fˆDZ ,
while the second term converges in probability to zero by the consistency of Sˆ−1
D¯Z
(t),
C(8), and the continuous mapping theorem. Hence, fˆDZ(Sˆ
−1
D¯Z
(t))
P−→ fDZ(S−1D¯Z(t)) as
nD, nD¯ →∞. A similar argument shows fˆD¯Z(Sˆ−1D¯Z(t)) is also consistent. The variance
estimator is a continuous function of these components, and under C(6) is consistent.
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Figure 1: Fictitious data for a marker Y and binary covariate Z = 0, 1. Under
scenario 1, P [Z = 1|D = 0] = 0.10 and P [Z = 1|D = 1] = 0.50. Under scenario
2, P [Z = 1|D = 0] = P [Z = 1|D = 1] = 0.50. (a) The densities of Y conditional
on Z = 0, conditional on Z = 1, marginally under scenario 1, and marginally under
scenario 2. The solid line represents the case density, and the dashed line the control
density. A common threshold of 2.5 is indicated. (b) The common covariate-speciﬁc
ROC curve (solid line), the pooled ROC curve under scenario 1 (dotted line) and the
pooled ROC curve under scenario 2 (dashed line) The performances of the common
threshold are indicated.
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Figure 2: Two examples to illustrate that the ROC curve for the risk score, R =
P [D = 1|Y, Z] is diﬀerent from the common covariate-speciﬁc ROC curve. In both
examples, (Y, Z) is bivariate normal. The ROC curve for R (dotted line) and the
common covariate-speciﬁc ROC curve (solid line) are shown. (a) Z is a good classiﬁer
but Y is not, and the two are relatively uncorrelated. (b) Both Y and Z are good
classiﬁers, and are highly correlated.
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Figure 3: ROC curves for PSA in the PHS data. (a) Age-speciﬁc ROC curves,
estimated using ROC-GLM. (b) The age-adjusted ROC curve, estimated using the
semi-parametric estimator (solid line) and ROC-GLM (dashed line). 95% conﬁdence
intervals, based on bootstrapped variance estimates, are overlaid at t = 0.025 and
t = 0.05.
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